+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Any value of podocyte B7-1 as a biomarker in human MCD and FSGS?



Any value of podocyte B7-1 as a biomarker in human MCD and FSGS?



American Journal of Physiology. Renal Physiology 310(5): F335



Minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS) are the most common causes of nephrotic syndrome in children and in young adults. Relapsing MCD carries the risk of severe complications and prolonged immunosuppression, whereas FSGS remains largely untreatable and urgently needs more effective treatments. Recently, induction of B7-1 (CD80), an immune-related protein expressed by antigen-presenting cells, was observed in podocytes of MCD and FSGS patients, suggesting that B7-1 plays a role in the pathogenesis of these diseases, and hence that abatacept, a B7-1 inhibitor, could be a possible treatment. Since previous studies raised serious concerns regarding the reliability of immunohistochemical assays for B7-1 detection and the efficacy of B7-1 inhibitory treatment, we investigated B7-1 podocyte expression in MCD and FSGS patients. Using different primary antibodies and immunohistochemical assays, no significant upregulation of podocyte B7-1 was detected in patients' biopsies compared with controls. To further confirm our findings, we analyzed mice with adriamycin-induced nephropathy, a model of human FSGS, and mice injected with LPS as additional control. Podocyte B7-1 was not observed in mice injected with adriamycin or LPS either. In conclusion, since B7-1 is not induced in podocyte of MCD and FSGS patients, the antiproteinuric action of abatacept, if confirmed, may not be the result of an effect on podocyte B7-1.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 057218169

Download citation: RISBibTeXText

PMID: 26697986

DOI: 10.1152/ajprenal.00510.2015


Related references

Loss of the podocyte-expressed transcription factor Tcf21/Pod1 results in podocyte differentiation defects and FSGS. Journal of the American Society of Nephrology 25(11): 2459-2470, 2014

Podocyte-Specific Sialylation-Deficient Mice Serve as a Model for Human FSGS. Journal of the American Society of Nephrology 30(6): 1021-1035, 2019

Podocyte Growing Pains in Adaptive FSGS. Journal of the American Society of Nephrology 28(10): 2825-2827, 2017

Footnote: orchestrating the podocyte and the immune system in FSGS. Pediatric and Developmental Pathology 7(2): 106-108, 2004

Losing their footing: Rac1 signaling causes podocyte detachment and FSGS. Kidney International 92(2): 283-285, 2017

FSGS as an Adaptive Response to Growth-Induced Podocyte Stress. Journal of the American Society of Nephrology 28(10): 2931-2945, 2017

Partial podocyte replenishment in experimental FSGS derives from nonpodocyte sources. American Journal of Physiology. Renal Physiology 310(11): F1397, 2016

Podocyte-Specific Deletion of Yes-Associated Protein Causes FSGS and Progressive Renal Failure. Journal of the American Society of Nephrology 27(1): 216-226, 2016

Podocyte repopulation by renal progenitor cells following glucocorticoids treatment in experimental FSGS. American Journal of Physiology. Renal Physiology 304(11): F1375, 2013

Mutations in podocyte genes are a rare cause of primary FSGS associated with ESRD in adult patients. Clinical Nephrology 78(1): 47-53, 2012

Fibrinogen links podocyte injury with Toll-like receptor 4 and is associated with disease activity in FSGS patients. Nephrology 23(5): 418-429, 2018

Podocyte phenotypes as defined by expression and distribution of GLEPP1 in the developing glomerulus and in nephrotic glomeruli from MCD, CNF, and FSGS. Experimental Nephrology 6(3): 234-244, May-June, 1998

Treatment with peroxisome proliferator-activated receptor-gamma agonist is protective in podocyte injury-associated FSGS. Journal of the American Society of Nephrology 14(Abstracts Issue): 123A, 2003

TNFα pathway blockade ameliorates toxic effects of FSGS plasma on podocyte cytoskeleton and β3 integrin activation. Pediatric Nephrology 27(12): 2217-2226, 2012

Treatment with 2,4-Dihydroxybenzoic Acid Prevents FSGS Progression and Renal Fibrosis in Podocyte-Specific Coq6 Knockout Mice. Journal of the American Society of Nephrology 2019:, 2019